Free Trial
→ Many investors are about to lose everything (From Porter & Company) (Ad)tc pixel Free ARVN Stock Alerts

Arvinas (ARVN) News Today

Arvinas logo
$7.35 +0.26 (+3.67%)
As of 01:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Arvinas Latest News

Arvinas (ARVN) Q3 2026 Earnings Call Transcript
November 3 at 6:12 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/arvinas-arvn-q3-2026-earnings-214349683.html
HC Wainwright Issues Pessimistic Forecast for Arvinas (NASDAQ:ARVN) Stock Price
November 3 at 12:41 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hc-wainwright-issues-pessimistic-forecast-for-arvinas-nasdaq-arvn-stock-price-2026-11-03/
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Estimates By $0.06 EPS
November 3 at 11:10 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/earnings-arvinas-nasdaq-arvn-releases-earnings-results-beats-estimates-by-006-eps-2026-11-03/
What Arvinas (ARVN) Said on Its Q3 Earnings Call
November 3 at 10:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/transcript-what-arvinas-arvn-said-on-its-q3-earnings-call-2026-11-03/
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 3 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/03/3394044/0/en/arvinas-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html
What To Expect From Arvinas Inc (ARVN) Q3 2026 Earnings
November 2 at 4:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/expect-arvinas-inc-arvn-q3-123846763.html
Arvinas Q3 2026 earnings preview
November 2 at 4:26 PM  |  msn.comhttps://www.msn.com/en-us/news/other/arvinas-q3-2026-earnings-preview/ar-AA2gBdxY
Arvinas, Inc. (ARVN) - What Are Analysts Saying About This Stock?
November 2 at 2:16 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173039
Arvinas, Inc. (ARVN) - What Are Brokerages Saying About This Stock?
November 2 at 2:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-arvinas-inc-arvn-what-are-brokerages-saying-about-this-stock-2026-11-02/
Arvinas (ARVN) Expected to Post Earnings on Tuesday
November 1 at 3:27 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31171385
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
October 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3389585/0/en/arvinas-announces-return-of-early-career-researcher-award-to-recognize-innovation-in-targeted-protein-degradation.html
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
October 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3388821/0/en/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026.html
Critical Comparison: Valneva (NASDAQ:VALN) and Arvinas (NASDAQ:ARVN)
October 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31158142
Arvinas, Inc. (ARVN) Analyst Insights, Price Targets & Recommendations - Yahoo Finance
October 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/ARVN/analyst-insights/
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN) and Ovid Therapeutics (OVID)
October 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BHC/pressreleases/5341770/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bausch-health-companies-bhc-arvinas-holding-company-arvn-and-ovid-therapeutics-ovid/
Arvinas, Inc. (NASDAQ:ARVN) Stock Has Average Price Target of $14.55
October 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-arvinas-inc-nasdaq-arvn-stock-has-average-price-target-of-1455-2026-10-08/
Arvinas' ARV-102 Shows Biomarker Changes In Parkinson's Phase 1 Trial
October 7, 2026  |  rttnews.comhttps://www.rttnews.com/3697174/arvinas-arv-102-shows-biomarker-changes-in-parkinson-s-phase-1-trial.aspx
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
October 7, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/arvinas-shares-novel-oculomotor-and-biomarker-data-from-phase-1-clinical-trial-of-arv-102-in-patients-with-parkinson-s-disease-1036604475
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376329/0/en/arvinas-shares-novel-oculomotor-and-biomarker-data-from-phase-1-clinical-trial-of-arv-102-in-patients-with-parkinson-s-disease.html
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and ...
October 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/arvinas-to-present-novel-biomarker-data-from-the-phase-1-clinical-trial-for-arv-102-a-protac-lrrk2-degrader-at-the-2026-international-congress-of-parkinson-s-disease-and-movement-disorders-1036591370
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373367/0/en/arvinas-to-present-novel-biomarker-data-from-the-phase-1-clinical-trial-for-arv-102-a-protac-lrrk2-degrader-at-the-2026-international-congress-of-parkinson-s-disease-and-movement-d.html
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3371315/0/en/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Arvinas Advances ARV-6723 Into Phase 1/2 Trial In Advanced Solid Tumors
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694299/arvinas-advances-arv-6723-into-phase-1-2-trial-in-advanced-solid-tumors.aspx
Arvinas Doses First Patient in Phase 1/2 Trial of ARV-6723 for Solid Tumors
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/arvinas-doses-first-patient-phase-113815253.html
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/arvinas-announces-first-patient-dosed-110000571.html
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate
September 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/28/3369737/0/en/arvinas-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-arv-6723-the-company-s-first-immuno-oncology-candidate.html
Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA) and Arvinas Holding Company (ARVN)
September 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OLMA/pressreleases/4608945/analysts-offer-insights-on-healthcare-companies-olema-pharmaceuticals-olma-and-arvinas-holding-company-arvn/
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947051-arvinas-inc-arvn-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
Arvinas出席第12届Cantor Fitzgerald全球医疗健康大会，管线进展成焦点
September 10, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3561482
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/arvinas-arvn-just-made-protein-062217023.html
Arvinas to Participate in Upcoming Investor Conferences
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3356234/0/en/arvinas-to-participate-in-upcoming-investor-conferences.html
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354568/0/en/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
August 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4941222-arvinas-veppanu-approval-underlines-degrader-platform-promise-i-am-bullish
Truist Financial Releases a Hold Rating on Arvinas Holding Company (ARVN)
August 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ARVN/pressreleases/3778078/truist-financial-releases-a-hold-rating-on-arvinas-holding-company-arvn/
Arvinas (ARVN) Q2 2026 Earnings Call Transcript
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/arvinas-arvn-q2-2026-earnings-180550795.html
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
August 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930109-arvinas-inc-arvn-q2-2026-earnings-call-transcript
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338149/0/en/arvinas-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Arvinas Q2 2026 earnings preview
August 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/arvinas-q2-2026-earnings-preview/ar-AA29k2B1
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334097/0/en/arvinas-to-report-second-quarter-2026-financial-results-on-august-4-2026.html
ARVN Share News Today
July 13, 2026  |  uk.investing.comhttps://uk.investing.com/equities/arvinas-holding-news/23
Andrew Saik Sells 5,696 Shares of Arvinas (NASDAQ:ARVN) Stock
June 25, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-arvn-insider-buying-and-selling-2026-06-25/
Arvinas Announces Chief Medical Officer Leadership Transition
June 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/arvinas-announces-chief-medical-officer-leadership-transition?utm_source=marketbeat.com&utm_medium=referral
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
June 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ARVN/pressreleases/36701785/arvinas-joins-the-michael-j-fox-foundations-lite-and-ppmi-programs-to-advance-new-therapies-targeting-lrrk2-for-parkinsons-disease/
Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)
June 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RLAY/pressreleases/2301281/analysts-conflicted-on-these-healthcare-names-arvinas-holding-company-arvn-lyell-immunopharma-lyel-and-relay-therapeutics-rlay/
Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease
June 5, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/06/04/10394396.htm
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development
June 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/arvinas-reprioritizes-pipeline-out-licenses-arv-806-development?utm_source=marketbeat.com&utm_medium=referral
Arvinas to Present at Jefferies Global Healthcare Conference
May 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/29/3303805/0/en/arvinas-to-present-at-jefferies-global-healthcare-conference.html
Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 2,209 Shares
May 23, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-arvn-insider-buying-and-selling-2026-05-23/
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN)
May 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/2099466/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-arvinas-holding-company-arvn/
Arvinas Employees Give Back During Company-wide Impact Day
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296793/0/en/arvinas-employees-give-back-during-company-wide-impact-day.html

Arvinas Media Mentions By Week

Arvinas Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARVN
News Sentiment
▼
0.13

0.42
▲
Average
Healthcare
News Sentiment

Arvinas News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARVN Articles
This Week
▼
12

5
▲
ARVN Articles
Average Week

Arvinas Trends on MarketBeat

This week vs. last week
Searches
1
Page Views
2,811
+36%
Get Arvinas News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Arvinas dated 11/3/2026.
From Our Partners
The AI Infrastructure Rush Is ON — Watch VDTA
Vertical Data Inc (OTCQB: VDTA) is building the layers beneath the AI boom - GPU hardware and financing, manag...
Trading Wire | Sponsoredtc pixel
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...
Behind the Markets | Sponsoredtc pixel
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...
Weiss Ratings | Sponsoredtc pixel
Many investors are about to lose everything
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...
Porter & Company | Sponsoredtc pixel
U.S. Army Advances 75-Year Rare Earth Deal With Nasdaq Firm
The Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...
The Tomorrow Investor | Sponsoredtc pixel
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...
Profits Run | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Stanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...
Brownstone Research | Sponsoredtc pixel